Searched query = "Dorabe syndrome", "Dravet syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||JPRN-jRCTs041190116||17/02/2020||17/02/2020||3D gait analysis and L-DOPA in Dravet syndrome.||3D gait analysis and effectiveness of L-DOPA on pathological gait in Dravet syndrome.||Dravet syndrome(severe myoclonic epilepsy in infant) |
Dravet syndrome, severe myoclonic epilepsy in infant;D004831
|Arm A:0) 3D gait analysis and RS-fMRI before medication 1) levodopa/carbidopa(5mg/kg/day or 300mg/day(more than 60kg)) given orally during 4-6weeks 2) second 3D gait analysis and RS-fMRI 3) reduce and stop medication durring 4weeks, no medication during 4-6weeks 4)third 3D gait analysis|
Arm B:0) 3D gait analysis and RS-fMRI before medication 1) 4-6weeks with no medication 2) second 3D gait analysis 3) levodopa/carbidopa given orally during 4-6weeks 4)third 3D gait analysis and second RS-fMRI
|Natsume Jun||NULL||Recruiting||>= 6age old||Not applicable||Both||20||Phase 4||Japan|